Hence, the potential hypothesis might be that there exists a percentage of patients with advanced NSCLC, of which the NLR might be decreased by EGFR-TKIs, who may benefit from salvage treatment with anti-PD-1 inhibitors after progression to TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.